Toutes les études
Actif, mais pas en recrutementPHASE1, PHASE2INTERVENTIONNEL

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

This research study is about a new drug, VX-670, for adults living with Myotonic Dystrophy Type 1 (DM1). The main goal is to check how safe the drug is when given at different doses, and how well it's tolerated by the body. Researchers also want to understand how the body processes the medicine and if it has any effects on the condition. Participants will be aged between 18 and 64 years. Some will receive the active drug (VX-670), while others will get a placebo (a dummy treatment). This is a standard way to test new medicines fairly. The study is divided into two parts to gather important information on both safety and initial signs of effectiveness.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE1, PHASE2
Sponsor
Vertex Pharmaceuticals Incorporated
Objectif d'inscription
47
Démarrer
20 Feb 2024
Achèvement estimé
02 Feb 2027

De quoi parle cette étude ?

This study is looking into a new treatment called VX-670 for a condition called Myotonic Dystrophy Type 1, often shortened to DM1. DM1 is a type of muscular dystrophy that can affect many parts of the body, including muscles. We want to understand if this new medicine is safe for people with DM1 and if it can help with the condition.

The study will involve giving participants either the new medicine, VX-670, or a 'placebo'. A placebo looks just like the real medicine but contains no active drug. This is common in medical research and helps us fairly compare the effects of the new medicine against not having it. By giving different doses, we can work out the best and safest amount of the medicine.

The information gathered from this study, especially in its early phases, helps us decide whether VX-670 could be a helpful treatment for DM1 in the future. It's an important step in developing new ways to manage this condition.

Points clés

  • Tests a new medicine (VX-670) for Myotonic Dystrophy Type 1 (DM1).
  • Aims to check safety and how the body handles the medicine.
  • Compares VX-670 to a placebo (dummy treatment).
  • Open to adults aged 18-64 with a confirmed DM1 diagnosis.
  • Requires regular clinic visits and health checks.
  • La participation est volontaire, et vous pouvez vous retirer à tout moment.

Qui peut être éligible ?

To join this study, you must have a confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1). This diagnosis needs to be supported by a genetic test showing a certain change (called a CTG repeat of at least 100). Also, your symptoms of DM1 must have started when you were older than one year old. You need to be between 18 and 64 years old to take part.

There are also some reasons why you might not be able to join. For example, if you have certain other health conditions or illnesses, you might not be eligible. This is to make sure the study is as safe as possible for everyone involved and that we can clearly see the effects of the new medicine.

Your study doctor will go through all the detailed requirements with you to see if this study is a good fit. It's important to be open about your full health history.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Do you have a personal diagnosis of Myotonic Dystrophy Type 1 (DM1)?
  2. Did your DM1 symptoms appear after you were one year old?
  3. Do you have a genetic test result confirming DM1 with at least 100 CTG repeats?
  4. Are you between 18 and 64 years old?
  5. Do you not have any other major health conditions that might prevent you from joining a study?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, you will have regular visits to the study clinic. During these visits, the study team will carry out various checks and assessments to see how you are doing. This often includes things like physical exams, blood tests, and other specific tests related to your condition. You will be given either the study medicine (VX-670) or a placebo, which you'll take as instructed by the study team.

The study has two parts. The first part will look at different single doses of the medicine, and the second part will look at giving the medicine multiple times. You will be closely monitored throughout your participation to ensure your safety and track any changes. The total length of time you'd be involved in the study will be explained in detail by the study team, including how many visits and follow-up checks you'll have.

Risques et avantages potentiels

Taking part in a study like this might offer a chance to receive a new medicine that could potentially help with your condition, though there's no guarantee. You might also find it helpful to contribute to medical research that could benefit others with DM1 in the future. However, there are also potential risks, as with any medicine. These could include side effects from the study drug, or even from the procedures (like blood tests). These risks will be fully explained, and your safety will be closely monitored throughout. Remember, you can choose to leave the study at any time, for any reason, without it affecting your usual medical care.

Emplacements (26)

  • Stanford Neuromuscular Research
    Code postal vérifié
    San Carlos, United States
  • University of Florida Clinical Research Center
    Code postal vérifié
    Gainesville, États-Unis
  • University of Kansas Medical Center
    Code postal vérifié
    Fairway, États-Unis
  • Boston Children's Hospital
    Code postal vérifié
    Boston, États-Unis
  • Washington University School of Medicine / St. Louis Children's Hospital
    Code postal vérifié
    Saint Louis, États-Unis
  • Wake Forest Baptist Health
    Code postal vérifié
    Winston-Salem, United States
  • University of Pennsylvania
    Code postal vérifié
    Philadelphie, États-Unis
  • Virginia Commonwealth University (Sanger Hall)
    Code postal vérifié
    Richmond, United States
  • Wesley Research Institute
    Code postal vérifié
    Auchenflower, Australia
  • Neuroscience Clinical Trials Unit, Alfred Brain
    Code postal vérifié
    Melbourne, Australie
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Code postal vérifié
    Leuven, Belgium
  • Hopital de Chicoutimi
    Code postal vérifié
    Chicoutimi, Canada

Questions fréquentes

What is Myotonic Dystrophy Type 1 (DM1)?

It's a long-term muscle disease that can cause muscle weakness and slowness, and affect other body systems, including the heart and brain.

Qu'est-ce qu'un 'placebo' ?

A placebo looks like the study medicine but doesn't contain any active drug. It helps researchers fairly compare how much the new drug helps versus not taking it.

Saurai-je si je reçois le vrai médicament ou le placebo ?

No, usually neither you nor the study team will know during the study. This helps ensure unbiased results.

Are there any costs involved for me?

Clinical trials generally cover all study-related medical costs. Check with the study team about travel or other expenses.

Combien de temps vais-je participer à l'étude ?

The total duration of your participation, including visits and follow-ups, will be clearly explained by the study team before you join.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.